Cumulative Dispensing of Oral Corticosteroids Over 12 Months in People with COPD
Angela T Burge,1,2 Narelle S Cox,1,3 Simone Dal Corso,1 Arwel W Jones,1 Fahrayhansyah Muhammad Faqih,1 Anne E Holland1– 4 1School of Translational Medicine, Monash University, Melbourne, VIC, Australia; 2Department of Physiotherapy, Alfred Health, Melbourne, VIC, Australia; 3Institute for Breathing...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-01-01
|
| Series: | International Journal of COPD |
| Subjects: | |
| Online Access: | https://www.dovepress.com/cumulative-dispensing-of-oral-corticosteroids-over-12-months-in-people-peer-reviewed-fulltext-article-COPD |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832592094792777728 |
|---|---|
| author | Burge AT Cox NS Dal Corso S Jones AW Faqih FM Holland AE |
| author_facet | Burge AT Cox NS Dal Corso S Jones AW Faqih FM Holland AE |
| author_sort | Burge AT |
| collection | DOAJ |
| description | Angela T Burge,1,2 Narelle S Cox,1,3 Simone Dal Corso,1 Arwel W Jones,1 Fahrayhansyah Muhammad Faqih,1 Anne E Holland1– 4 1School of Translational Medicine, Monash University, Melbourne, VIC, Australia; 2Department of Physiotherapy, Alfred Health, Melbourne, VIC, Australia; 3Institute for Breathing and Sleep, Melbourne, VIC, Australia; 4Department of Respiratory Medicine, Alfred Health, Melbourne, VIC, AustraliaCorrespondence: Angela T Burge, Respiratory Research@Alfred, Monash University, Level 6 The Alfred Centre, 99 Commercial Road, Melbourne, VIC, 3004, Australia, Email angela.burge@monash.eduPurpose: Oral corticosteroids (OCS) are recommended for the treatment of exacerbations in people with COPD; however, high cumulative lifetime doses (≥ 1000mg prednisolone-equivalent) are associated with adverse health effects. This issue is well defined in asthma but is less well understood in COPD. The aim of this study was to examine cumulative OCS dispensed to people with COPD over 12 months.Patients and Methods: This was a secondary analysis of data from two randomised controlled trials involving people with COPD followed up for 12 months following pulmonary rehabilitation. Clinical and administrative (respiratory-related hospital admissions and emergency presentations, dispensed OCS and COPD maintenance medications) data were examined to determine cumulative OCS dose relative to the 1000mg threshold and the relationship with clinical features.Results: Of 232 participants (126 females, age mean 68 ± SD 9 years, FEV1 53 ± 22% predicted), 48% (n = 112) were dispensed OCS at least once over 12 months. Sixty-two participants (26%) were dispensed ≥ 1000mg. Participants with a high cumulative dose were more likely to have had a respiratory admission (OR 4.1, 95% CI 2.3 to 8.7) and greater breathlessness (modified Medical Research Council scale ≥ 2, OR 2.5, 95% CI 1.3 to 5.0); no relationship with disease severity or maintenance medications was demonstrated.Conclusion: One in four people with COPD were dispensed unsafe lifetime cumulative OCS doses over a period of only 12 months. Further work is needed to determine the magnitude of this issue in COPD and strategies to address exposure to high doses of OCS.Keywords: exacerbations, systemic corticosteroids, prescriptions, side effects |
| format | Article |
| id | doaj-art-e2267974386c4343865fb2602bf52d12 |
| institution | Kabale University |
| issn | 1178-2005 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | International Journal of COPD |
| spelling | doaj-art-e2267974386c4343865fb2602bf52d122025-01-21T16:58:06ZengDove Medical PressInternational Journal of COPD1178-20052025-01-01Volume 2014915899404Cumulative Dispensing of Oral Corticosteroids Over 12 Months in People with COPDBurge ATCox NSDal Corso SJones AWFaqih FMHolland AEAngela T Burge,1,2 Narelle S Cox,1,3 Simone Dal Corso,1 Arwel W Jones,1 Fahrayhansyah Muhammad Faqih,1 Anne E Holland1– 4 1School of Translational Medicine, Monash University, Melbourne, VIC, Australia; 2Department of Physiotherapy, Alfred Health, Melbourne, VIC, Australia; 3Institute for Breathing and Sleep, Melbourne, VIC, Australia; 4Department of Respiratory Medicine, Alfred Health, Melbourne, VIC, AustraliaCorrespondence: Angela T Burge, Respiratory Research@Alfred, Monash University, Level 6 The Alfred Centre, 99 Commercial Road, Melbourne, VIC, 3004, Australia, Email angela.burge@monash.eduPurpose: Oral corticosteroids (OCS) are recommended for the treatment of exacerbations in people with COPD; however, high cumulative lifetime doses (≥ 1000mg prednisolone-equivalent) are associated with adverse health effects. This issue is well defined in asthma but is less well understood in COPD. The aim of this study was to examine cumulative OCS dispensed to people with COPD over 12 months.Patients and Methods: This was a secondary analysis of data from two randomised controlled trials involving people with COPD followed up for 12 months following pulmonary rehabilitation. Clinical and administrative (respiratory-related hospital admissions and emergency presentations, dispensed OCS and COPD maintenance medications) data were examined to determine cumulative OCS dose relative to the 1000mg threshold and the relationship with clinical features.Results: Of 232 participants (126 females, age mean 68 ± SD 9 years, FEV1 53 ± 22% predicted), 48% (n = 112) were dispensed OCS at least once over 12 months. Sixty-two participants (26%) were dispensed ≥ 1000mg. Participants with a high cumulative dose were more likely to have had a respiratory admission (OR 4.1, 95% CI 2.3 to 8.7) and greater breathlessness (modified Medical Research Council scale ≥ 2, OR 2.5, 95% CI 1.3 to 5.0); no relationship with disease severity or maintenance medications was demonstrated.Conclusion: One in four people with COPD were dispensed unsafe lifetime cumulative OCS doses over a period of only 12 months. Further work is needed to determine the magnitude of this issue in COPD and strategies to address exposure to high doses of OCS.Keywords: exacerbations, systemic corticosteroids, prescriptions, side effectshttps://www.dovepress.com/cumulative-dispensing-of-oral-corticosteroids-over-12-months-in-people-peer-reviewed-fulltext-article-COPDexacerbationssystemic corticosteroidsprescriptionsside effects |
| spellingShingle | Burge AT Cox NS Dal Corso S Jones AW Faqih FM Holland AE Cumulative Dispensing of Oral Corticosteroids Over 12 Months in People with COPD International Journal of COPD exacerbations systemic corticosteroids prescriptions side effects |
| title | Cumulative Dispensing of Oral Corticosteroids Over 12 Months in People with COPD |
| title_full | Cumulative Dispensing of Oral Corticosteroids Over 12 Months in People with COPD |
| title_fullStr | Cumulative Dispensing of Oral Corticosteroids Over 12 Months in People with COPD |
| title_full_unstemmed | Cumulative Dispensing of Oral Corticosteroids Over 12 Months in People with COPD |
| title_short | Cumulative Dispensing of Oral Corticosteroids Over 12 Months in People with COPD |
| title_sort | cumulative dispensing of oral corticosteroids over 12 months in people with copd |
| topic | exacerbations systemic corticosteroids prescriptions side effects |
| url | https://www.dovepress.com/cumulative-dispensing-of-oral-corticosteroids-over-12-months-in-people-peer-reviewed-fulltext-article-COPD |
| work_keys_str_mv | AT burgeat cumulativedispensingoforalcorticosteroidsover12monthsinpeoplewithcopd AT coxns cumulativedispensingoforalcorticosteroidsover12monthsinpeoplewithcopd AT dalcorsos cumulativedispensingoforalcorticosteroidsover12monthsinpeoplewithcopd AT jonesaw cumulativedispensingoforalcorticosteroidsover12monthsinpeoplewithcopd AT faqihfm cumulativedispensingoforalcorticosteroidsover12monthsinpeoplewithcopd AT hollandae cumulativedispensingoforalcorticosteroidsover12monthsinpeoplewithcopd |